· The collaboration includes up to three development programs each year, potentially reaching a total deal value exceeding $1 billion based on achieving specific milestones.
Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [July 28, 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK-based company specializing in ocular therapeutics and drug delivery technologies, have announced a strategic collaboration and licensing agreement to develop innovative, long-lasting treatments for eye conditions.
Globally, vision loss affects millions of individuals with eye diseases, progressively impacting their independence and connection to the world. Boehringer Ingelheim, with its diverse eye health pipeline including four assets in Phase II, is dedicated to preserving the retina, safeguarding people’s lifestyles, and preventing vision loss. Treating eye diseases often requires frequent injections into the eye, which can be burdensome for patients. Re-Vana’s drug delivery technology aims to reduce the frequency of these injections by slowly releasing treatments over six to 12 months. Reducing the burden of treatment may improve patient compliance and potentially lead to better outcomes. Boehringer Ingelheim plans to explore combining this technology with its own eye health pipeline.
“We are excited to partner with Re-Vana to advance the possibilities in eye health,” stated Nedim Pipic, Global Head of Mental Health, Eye Health, and Emerging Areas at Boehringer Ingelheim. “Together, we aim to overcome the limitations of current treatments, helping people maintain their vision with fewer injections. This partnership marks a significant step in our mission to protect vision and alleviate the burden on patients.”
“The strategic collaboration with Boehringer Ingelheim is a transformative moment for Re-Vana,” said Michael O’Rourke, CEO of Re-Vana. “By combining our extended-release platform with Boehringer Ingelheim’s world-class research and development capabilities and eye health pipeline, we aim to develop a new generation of long-acting eye disease treatments that provide clinical and quality-of-life benefits for patients.”
The collaboration aims for Boehringer Ingelheim to add up to three projects annually across various therapeutic approaches. The companies will jointly manage Re-Vana’s feasibility and development activities for the extended-release programs. Boehringer Ingelheim will then assume full responsibility for clinical development, regulatory approval, and global commercialization. The agreement grants Boehringer Ingelheim target exclusivity and includes upfront, development, regulatory, and commercial milestone payments to Re-Vana. The total potential deal value for the initial three targets could exceed $1 billion, in addition to royalty payments on net sales.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company focused on both human and animal health. A top investor in research and development, the company develops innovative therapies to improve and extend lives in areas with significant unmet medical needs. As an independent company since 1885, Boehringer Ingelheim takes a long-term approach, integrating sustainability throughout its value chain. Approximately 54,500 employees serve over 130 markets to build a healthier, more sustainable future. Learn more at (Global) or (UK).
About Re-Vana Therapeutics
Re-Vana Therapeutics Ltd, established in 2016 as a spin-out from Queen’s University Belfast, is an ocular therapeutics and innovative ocular drug delivery company located in Belfast, Northern Ireland, and is a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida.
Re-Vana is venture-backed by leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners, and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland, and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained-release anti-VEGF asset. Learn more at
Intended Audiences Notice
This press release originates from our Corporate Headquarters in Ingelheim, Germany, and is intended to provide information about our global operations. Please note that approval statuses and product labels may vary by country, and country-specific press releases may have been issued where we operate.
Media Contacts
Boehringer Ingelheim:
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
Linda Ruckel
Boehringer Ingelheim
Innovation Unit Communications
Re-Vana:
Michele Gray
Gray Communications, LLC
Michele@mgraycommunications.com
+1 917 449 9250
